LALPATHLAB

DR. LAL PATHLABS

Large Cap BSE: 539524 NSE: LALPATHLAB
₹2478.15
39.4 (1.62%)
  • Advice
  • Hold
As on 04 December, 2022 | 14:13

Dr. Lal Pathlabs Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in DR. LAL PATHLABS

Start SIP

Dr. Lal Pathlabs Share Price

Dr. Lal Pathlabs Share Returns

  • Over 1 Month -6.06%
  • Over 3 Month 1.59%
  • Over 6 Month 15.62%
  • Over 1 Year -34.67%

Dr. Lal Pathlabs Key Statistics

P/E Ratio 83.3
PEG Ratio -2.2
Market Cap Cr 20,656
Price to Book Ratio 13.4
EPS 41.3
Dividend 0.5
Relative Strength Index 52.55
Money Flow Index 74.8
MACD Signal -15.5
Average True Range 73.6

Dr. Lal Pathlabs Investment Rating

  • Master Rating:
  • Dr Lal Pathlabs has an operating revenue of Rs. 2,018.90 Cr. on a trailing 12-month basis. An annual revenue growth of 31% is outstanding, Pre-tax margin of 23% is great, ROE of 22% is exceptional. The company has a reasonable debt to equity of 11%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its key moving averages, around 0% and 3% from 50DMA and 200DMA. It needs to stay above these levels to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 9% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 53 which is a POOR score indicating inconsistency in earnings, a RS Rating of 34 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 98 indicates it belongs to a poor industry group of Medical-Services and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Dr. Lal Pathlabs Financials
IndicatorSep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021
Oper Rev Qtr Cr 467439415423470565404
Operating Expenses Qtr Cr 337330310323337392291
Operating Profit Qtr Cr 130109105100133173113
Depreciation Qtr Cr 21192219181718
Interest Qtr Cr 108119444
Tax Qtr Cr 28222022324226
Net Profit Qtr Cr 798065629412379

Dr. Lal Pathlabs Technicals

EMA & SMA

Current Price
2478.15
39.4 (1.62%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • 2450.14
  • 50 Day
  • 2452.81
  • 100 Day
  • 2443.07
  • 200 Day
  • 2529.7
  • 20 Day
  • 2443.4
  • 50 Day
  • 2475.75
  • 100 Day
  • 2405.25
  • 200 Day
  • 2405.76

Dr. Lal Pathlabs Resistance and Support

PIVOT
₹2445.94
Resistance
First Resistance 2461.77
Second Resistance 2484.79
Third Resistance 2500.62
RSI 52.55
MFI 74.8
MACD Single Line -15.5
MACD -12.19
Support
First Resistance 2422.92
Second Resistance 2407.09
Third Resistance 2384.07

Dr. Lal Pathlabs Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 255,431 11,816,238 46.26
Week 189,895 8,480,693 44.66
1 Month 282,926 7,854,030 27.76
6 Month 275,729 7,359,196 26.69

Dr. Lal Pathlabs Result Highlights

Dr. Lal Pathlabs Synopsis

NSE-Medical-Services

Dr. Lal Pathlabs Ltd is involved in the business activities of Other human health activities. Company’s Total Operating Revenue is Rs. 1872.71 Cr. and Equity Capital is Rs. 83.35 Cr. for the Year ended 31/03/2022. Dr. Lal Pathlabs Ltd. is a Public Limited Listed company incorporated on 14/02/1995 and has its registered office in the State of Delhi, India. Company’s Corporate Identification Number(CIN) is L74899DL1995PLC065388 and registration number is 065388.
Market Cap 20,656
Sales 1,744
Shares in Float 3.75
No of funds 280
Yield 0.48
Book Value 13.99
U/D Vol ratio 1.3
LTDebt / Equity 11
Alpha -0.16
Beta 0.91

Dr. Lal Pathlabs

Owner NameSep-22Jun-22Mar-22Dec-21
Promoters 55.05%55.05%55.23%
Mutual Funds 2.76%2.83%3.32%
Insurance Companies 2.33%2.46%2.37%
Foreign Portfolio Investors 23.26%22.37%23.44%
Financial Institutions/ Banks
Individual Investors 8.23%10.44%9.03%
Others 8.37%6.85%6.61%

Dr. Lal Pathlabs Management

Name Designation
Brig.(Hony) Dr. Arvind Lal Executive Chairman
Dr. Om Prakash Manchanda Managing Director
Dr. Vandana Lal Executive Director
Mr. Rahul Sharma Non Executive Director
Mr. Anoop Mahendra Singh Independent Director
Mr. Sunil Varma Lead Independent Director
Mr. Harneet Singh Chandhoke Independent Director
Dr. Saurabh Srivastava Independent Director
Mrs. Somya Satsangi Independent Director
Dr. Archana Lal Erdmann Non Executive Director

Dr. Lal Pathlabs Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Dr. Lal Pathlabs Corporate Action

Date Purpose Remarks
2022-11-08 Quarterly Results
2022-07-28 Quarterly Results & Interim Dividend
2022-05-17 Audited Results & Final Dividend
2022-02-10 Quarterly Results
2021-10-26 Quarterly Results
Date Purpose Remarks
2022-08-09 INTERIM Rs.6.00 per share(60%)Interim Dividend
2022-06-23 FINAL Rs.6.00 per share(60%)Final Dividend
2021-08-22 INTERIM Rs.6.00 per share(60%)Interim Dividend
2021-07-22 FINAL Rs.8.00 per share(80%)Final Dividend
2021-02-10 INTERIM Rs.6.00 per share (60%) Second Interim Dividend

Dr. Lal Pathlabs MF Shareholding

Name Amount(cr)
UTI Flexi Cap Fund Regular Plan Growth 26133
Kotak Equity Opportunities Fund Growth 11370
UTI Mid Cap Fund Regular Plan Growth 7348
UTI Unit Linked Insurance 5262
NJ Balanced Advantage Fund Regular Growth 4826

Dr. Lal Pathlabs FAQs

What is Share Price of Dr. Lal Pathlabs ?

Dr. Lal Pathlabs share price is ₹2478 As on 04 December, 2022 | 13:59

What is the Market Cap of Dr. Lal Pathlabs ?

The Market Cap of Dr. Lal Pathlabs is ₹20655.9 Cr As on 04 December, 2022 | 13:59

What is the P/E ratio of Dr. Lal Pathlabs ?

The P/E ratio of Dr. Lal Pathlabs is 83.3 As on 04 December, 2022 | 13:59

What is the PB ratio of Dr. Lal Pathlabs ?

The PB ratio of Dr. Lal Pathlabs is 13.4 As on 04 December, 2022 | 13:59

Q2FY23